US Top Rating Updates on 1/30: TSLA, LMT, SHOP, LYFT and More
![US Top Rating Updates on 1/30: TSLA, LMT, SHOP, LYFT and More](https://ussnsimg.moomoo.com/407952123113166607.png/bigmoo)
Tesla Stock Earns Upgrade to Buy on 'Misguided Pricing Concerns'
Despite seeing a "softer demand picture" in 2023 facing the global auto manufacturers, Berenberg upgraded $Tesla (TSLA.US)$ stock to Buy from Hold. While Tesla shares moved lower in the closing months of 2022 on several catalysts, including price cuts, Berenberg analysts said such moves are "an investment in growth." Their new price target on Tesla stock stands at $200 per share.
Edwards Lifesciences Downgraded to Neutral From Overweight at Piper Sandler
Piper Sandler analyst Adam Maeder downgraded $Edwards Lifesciences (EW.US)$ to Neutral from Overweight with a price target of $80, down from $95. Piper's doctor survey suggests slower than expected transcatheter aortic valve replacement and transcatheter mitral market growth in future years, the analyst tells investors in a research note.
Sanofi, Regeneron Dupixent Gets Approval in EU for Expanded Use in Eosinophilic Esophagitis
The European Commission (EC) approved $Sanofi (SNY.US)$ and $Regeneron Pharmaceuticals (REGN.US)$' Dupixent to treat eosinophilic esophagitis (EoE) in patients 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not eligible for conventional medicinal therapy.
Source: Seeking Alpha, The Fly
Disclaimer: The content should not be relied on as advice or recommendation.
Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.
Read more
Comment
Sign in to post a comment